NCT06228794Recruiting
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
The Prognostic Value of Circulating Plasma Cells Quantified by Multiparameter Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
Source: ClinicalTrials.gov · Last updated 21 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 458 (estimated)
- First submitted
- 19 Jan 2024
- Start date
- 1 Apr 2024
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Diseases
- Multiple myeloma
- NCT number
- NCT06228794
What you commit to
- Study type: Observational
- Planned participants: 458
- From 1 Apr 2024 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received therapy for multiple myeloma.
Other illness
- Imminent or emerging infection.
- Known to be seropositive for a history of HIV.
Other
- Patients meeting any of the following exclusion criteria will not be included in the study.
- Patients diagnosed with monoclonal gammopathy of undetermined significance, smoldering myeloma, nonsecretory myeloma, plasma cell leukemia, amyloidosis, waldenstrom macroglobulinemia or POEMS.
- A participant is a woman who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this trial.
- Known or suspected of not being able to comply with the study protocol.
Who the study is looking for
- Patients must meet all of the following inclusion criteria.
- Newly diagnosed multiple myeloma patients.
- Patients without any previous anti-myeloma treatment.
- Age: 18-80years old (adult).
- No history of cancer.
- Informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.